CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Twi Biotechnology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Twi Biotechnology Inc
8F, No.41, Lane 221, Kang Chien Road
Nei Hu District
Phone: +886 226571788p:+886 226571788 TAIPEI, 114  Taiwan Ticker: 66106610
Business Summary
TWi Biotechnology, Inc. is a Taiwan-based clinical stage biopharmaceutical company specializing in the development of new drugs for unmet medical needs, especially in diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. Its product development pipeline includes two drug candidates for treating type II diabetes, arthritis, and immunodermatology diseases and others. It’s still in the research and development stage, its operating income is the contract revenue from the signing of the contract with the Castal Creek Pharmaceuticals (CCP) about its drug AC-203 for the treatment of epidermolysis bullosa (EB). It mainly aims at America market.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board YijunWu 12/27/2023 12/2/2019
General Manager, Chief Medical Officer Cheng-EnTsai 1/1/2024 12/27/2023
Deputy General Manager-Clinical Research Division PeifangCai 4/14/2023 4/14/2023
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 28 (As of 12/31/2018)
Outstanding Shares: 87,649,395 (As of 3/13/2024)
Shareholders: 476
Stock Exchange: TPO
Fax Number: +886 226570270


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024